Equillium Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) Transcript
Hello, everyone, and welcome to this next in our series of fireside chats as part of the H.C. Wainwright Conference, focusing on autoimmune and inflammatory skin conditions within the context of dermatology. My name is Ram Selvaraju. I'm a managing director and senior healthcare equity research analyst here at H.C. Wainwright. I'm joined here by Steve Connelly and Bruce Steel from the management team of Equillium.
Equillium is currently traded on the NASDAQ under the ticker symbol EQ. We cover Equillium with a buy rating. I think it would be helpful perhaps just to contextualize things for our audience.
Bruce, if you could describe Equillium's original genesis around the molecule known as itolizumab, the fact that the company has recently executed a transformative transaction to put that company into the hands of Ono. And also then we can proceed to discuss Equillium's focus with respect to its endogenous pipeline, on particular, dermatological condition, alopecia areata. Bruce?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
